LPAAT-β in Ovarian Cancer: Its Role in Tumor Grading and Prognosis
Author Information
Author(s): Niesporek S, Denkert C, Weichert W, Köbel M, Noske A, Sehouli J W, Singer J W, Dietel M, Hauptmann S
Primary Institution: Charité University Hospital
Hypothesis
The study investigates the expression of LPAAT-β in ovarian carcinoma and its correlation with tumor grading and prognosis.
Conclusion
LPAAT-β is upregulated in ovarian cancer and is associated with poorer prognosis, especially in patients younger than 60 years.
Supporting Evidence
- LPAAT-β mRNA was found in all ovarian tumors examined.
- Expression of LPAAT-β protein was significantly increased in ovarian carcinomas compared to benign ovarian tissue.
- LPAAT-β expression was positively associated with higher tumor grade and mitotic index.
- Expression of LPAAT-β was significantly linked to reduced overall survival time in younger patients.
Takeaway
This study found that a protein called LPAAT-β is more common in bad types of ovarian cancer and can help predict how well younger patients will do.
Methodology
The expression of LPAAT-β was evaluated using reverse transcriptase–polymerase chain reaction and immunohistochemistry in ovarian cell lines and tumor samples.
Limitations
The study had a relatively small patient number, which may limit the power of survival analysis.
Participant Demographics
Median age at surgery was 57 years, with a range from 28 to 85 years; 71% had invasive ovarian carcinoma.
Statistical Information
P-Value
P=0.024 for overall survival in patients younger than 60 years with LPAAT-β-positive tumors.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website